Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;9(12):2566-77.
doi: 10.4161/hv.26088. Epub 2013 Aug 16.

Advances in the study of HLA-restricted epitope vaccines

Lingxiao Zhao  1 , Min Zhang  1 , Hua Cong  1
Affiliations
Review

Advances in the study of HLA-restricted epitope vaccines

Lingxiao Zhao et al. Hum Vaccin Immunother. 2013 Dec.

Abstract

Vaccination is a proven strategy for protection from disease. An ideal vaccine would include antigens that elicit a safe and effective protective immune response. HLA-restricted epitope vaccines, which include T-lymphocyte epitopes restricted by HLA alleles, represent a new and promising immunization approach. In recent years, research in HLA-restricted epitope vaccines for the treatment of tumors and for the prevention of viral, bacterial, and parasite-induced infectious diseases have achieved substantial progress. Approaches for the improvement of the immunogenicity of epitope vaccines include (1) improving the accuracy of the methods used for the prediction of epitopes, (2) making use of additional HLA-restricted CD8(+) T-cell epitopes, (3) the inclusion of specific CD4(+) T-cell epitopes, (4) adding B-cell epitopes to the vaccine construction, (5) finding more effective adjuvants and delivery systems, (6) using immunogenic carrier proteins, and (7) using multiple proteins as epitopes sources. In this manuscript, we review recent research into HLA-restricted epitope vaccines.

Keywords: HLA restriction; MHC; adjuvant; bioinformatic; epitope vaccine.

PubMed Disclaimer

References

    1. Jenner E. An inquiry into the causes and effects of the Variolae Vaccinae A disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the Cow Pox. London: Printed for the author by Sampson Low, 1798
    1. O’Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 2001;18:69–85. doi: 10.1016/S1389-0344(01)00101-0. - DOI - PubMed
    1. Hämmerling GJ, Vogt AB, Kropshofer H. Antigen processing and presentation--towards the millennium. Immunol Rev. 1999;172:5–9. doi: 10.1111/j.1600-065X.1999.tb01351.x. - DOI - PubMed
    1. Gras S, Burrows SR, Turner SJ, Sewell AK, McCluskey J, Rossjohn J. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev. 2012;250:61–81. doi: 10.1111/j.1600-065X.2012.01159.x. - DOI - PubMed
    1. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature. 1974;251:547–8. doi: 10.1038/251547a0. - DOI - PubMed

Publication types

MeSH terms